| Literature DB >> 34134709 |
Rajdeep Pooni1, Tova Ronis2, Tzielan Lee3.
Abstract
BACKGROUND: To characterize various aspects of telemedicine use by pediatric rheumatology providers during the recent pandemic including provider acceptability of telehealth practices, clinical reliability, and clinical appropriateness.Entities:
Keywords: COVID-19; Healthcare delivery services; Telehealth; Telemedicine
Mesh:
Year: 2021 PMID: 34134709 PMCID: PMC8206874 DOI: 10.1186/s12969-021-00565-7
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Respondent roles and years experience
| Pediatric Rheumatologist | 157 (70.4) |
| Other Subspecialists/Providers | 3 (1.3) |
| Resident/Fellow Trainees | 41 (18.4) |
| Advanced Practice Providers | 6 (2.7) |
| Nurse | 2 (0.08) |
| Social Worker | 1 (0.04) |
| Other Research Staff | 9 (4.0) |
| Did not answer | 4 (1.8) |
| Total | 223 |
| Mean Years Practice (Total) | 13.2 years |
| Range Years Practice | 0 to 48 years |
| Number omitted/no answer | 68 |
Exam components by percent selected “able to complete reliably”
| Exam Component | Number selected as reliably done by video | (%) |
|---|---|---|
| MSK hands/wrists/elbows | 101 | 62.7 |
| MSK: cervical | 100 | 62.1 |
| Mental Status | 95 | 59.0 |
| MSK knees/ankles | 91 | 56.5 |
| Extremities | 85 | 52.8 |
| Skin | 85 | 52.8 |
| MSK: TMJ | 75 | 46.6 |
| Eye exam (external only) | 71 | 44.1 |
| MSK hips | 60 | 37.3 |
| Oral Exam | 57 | 35.4 |
| MSK Spine | 53 | 32.9 |
| MSK strength | 47 | 29.2 |
| Neurologic exam | 21 | 13.0 |
| Respiratory | 14 | 8.7 |
| GI exam | 4 | 2.5 |
| CV | 3 | 1.9 |
Encounter type by number selected as “in-person” appropriate only
| Encounter Type | Number selected in-person only | % selected in-person only |
|---|---|---|
| Follow-up due to concern for flare | 120 | 53.8% |
| New patient consultations | 107 | 47.9% |
| Triage for anticipated hospitalization | 106 | 47.5% |
| Patient concern for worsening condition | 78 | 34.9% |
| Injection teaching | 57 | 25.5% |
| Need for labs | 22 | 9.8% |
| Routine follow-up visits | 15 | 6.7% |
Fig. 1Assessment of clinical components of encounters by components